Compare Baker Hughes Co (BKR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Novo Nordisk A/S — how do they compare? Baker Hughes Co trades at $64.74 (market cap $64.34B), while Novo Nordisk A/S trades at $45.8 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 3.2× Baker Hughes Co's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| BKR | NVO | |
|---|---|---|
Market Cap | $64.34B | $207.85B |
Sector | Energy | Health |
52-Week High | $69.67 | $63.98 |
52-Week Low | $42.51 | $35.29 |
Enterprise Value | $64.86B | $222.55B |
Dividend Yield | 1.42% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
